drugset
drugset / Trial / NCT06338293

Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques

NCT06338293 ↗

Phase 4 Recruiting 40 enrolled Nanjing First Hospital, Nanjing Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

Effects of inclisiran + statins vs. statins on the morphology and vascular function of coronary vulnerable plaques, in order to provide a better treatment and more detailed imaging basis for the treatment of coronary vulnerable plaques.

Timeline

Start
2024-03-15
Primary completion
2025-06-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Inclisiran Small interfering RNA (siRNA) 284 mg Subcutaneous
Background Rosuvastatin Small molecule 20 mg —

Indications

coronary artery disorder